Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia

WAG (Wendy) Stams; Monique den Boer; Berna Beverloo; Jules Meijerink; ER van Wering; GE Janka-Schaub; Rob Pieters

doi:10.1158/1078-0432.CCR-04-1829

Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia

WAG (Wendy) Stams, Monique den Boer, Berna Beverloo, Jules Meijerink, ER van Wering, GE Janka-Schaub, Rob Pieters

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2974-2980
Number of pages	7
Journal	Clinical Cancer Research
Volume	11
Issue number	8
DOIs	https://doi.org/10.1158/1078-0432.CCR-04-1829
Publication status	Published - 2005

Research programs

EMC MGC-02-96-01
EMC MM-02-54-03

Access to Document

10.1158/1078-0432.CCR-04-1829

http://hdl.handle.net/1765/13784

Cite this

Stams, WAG., den Boer, M., Beverloo, B., Meijerink, J., van Wering, ER., Janka-Schaub, GE., & Pieters, R. (2005). Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clinical Cancer Research, 11(8), 2974-2980. https://doi.org/10.1158/1078-0432.CCR-04-1829

@article{4f1c4009b2334974b1893a04d62594b0,

title = "Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia",

author = "Stams, {WAG (Wendy)} and {den Boer}, Monique and Berna Beverloo and Jules Meijerink and {van Wering}, ER and GE Janka-Schaub and Rob Pieters",

year = "2005",

doi = "10.1158/1078-0432.CCR-04-1829",

language = "Undefined/Unknown",

volume = "11",

pages = "2974--2980",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

Stams, WAG, den Boer, M, Beverloo, B, Meijerink, J, van Wering, ER, Janka-Schaub, GE & Pieters, R 2005, 'Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia', Clinical Cancer Research, vol. 11, no. 8, pp. 2974-2980. https://doi.org/10.1158/1078-0432.CCR-04-1829

Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. / Stams, WAG (Wendy); den Boer, Monique; Beverloo, Berna et al.
In: Clinical Cancer Research, Vol. 11, No. 8, 2005, p. 2974-2980.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia

AU - Stams, WAG (Wendy)

AU - den Boer, Monique

AU - Beverloo, Berna

AU - Meijerink, Jules

AU - van Wering, ER

AU - Janka-Schaub, GE

AU - Pieters, Rob

PY - 2005

Y1 - 2005

U2 - 10.1158/1078-0432.CCR-04-1829

DO - 10.1158/1078-0432.CCR-04-1829

M3 - Article

SN - 1078-0432

VL - 11

SP - 2974

EP - 2980

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 8

ER -